Literature DB >> 7505044

Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers.

L Mattsson1, A Sönnerborg, O Weiland.   

Abstract

Thirty-nine of 61 prospectively followed patients who had had acute non-A, non-B hepatitis in 1978 were clinically reexamined in 1991 and tested for antibodies to hepatitis C virus (anti-HCV) with a second generation ELISA and RIBA and for HCV RNA by PCR. Acute hepatitis C was diagnosed in stored sera from 1978 in 24 patients, who were found still to be anti-HCV positive in 1991, and 16 of them were also HCV RNA positive. The majority of anti-HCV positive patients with or without HCV RNA had elevated serum ALT levels 13 years after onset of their acute hepatitis C. After 13 years follow-up, 1.6% of the patients had died of end-stage liver disease, 8% of anti-HCV positive patients had histologically confirmed liver cirrhosis, 79% of anti-HCV positive patients were judged to have chronic infection, whereas 21% seemed to have recovered. To conclude, we found that a majority of our patients with acute symptomatic hepatitis C continued to be viraemic 13 years after onset of hepatitis C, and that all continued to be anti-HCV positive by second-generation ELISA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505044     DOI: 10.1111/j.1600-0676.1993.tb00644.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  16 in total

Review 1.  Histopathology and detection of hepatitis C virus in liver.

Authors:  P J Scheuer; K Krawczynski; A P Dhillon
Journal:  Springer Semin Immunopathol       Date:  1997

2.  Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

Authors:  U Siebert; G Sroczynski; S Rossol; J Wasem; U Ravens-Sieberer; B M Kurth; M P Manns; J G McHutchison; J B Wong
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

3.  Liver fibrosis progression in hepatitis C virus infection after seroconversion.

Authors:  Adeel A Butt; Peng Yan; Vincent Lo Re; David Rimland; Matthew B Goetz; David Leaf; Matthew S Freiberg; Marina B Klein; Amy C Justice; Kenneth E Sherman
Journal:  JAMA Intern Med       Date:  2015-02       Impact factor: 21.873

4.  Expression of hepatitis C virus core protein in hepatocytes does not modulate proliferation or apoptosis of CD8+ T cells.

Authors:  Young-Hee Jin; I Nicholas Crispe; Sun Park
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

5.  Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance.

Authors:  E Spada; A Mele; A Berton; L Ruggeri; L Ferrigno; A R Garbuglia; M P Perrone; G Girelli; P Del Porto; E Piccolella; M U Mondelli; P Amoroso; R Cortese; A Nicosia; A Vitelli; A Folgori
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

6.  Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study.

Authors:  Stuart C Gordon; Lois E Lamerato; Loralee B Rupp; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu Teshale; Fujie Xu; Joseph A Boscarino; Vinutha Vijayadeva; Mark A Schmidt; Nancy Oja-Tebbe; Mei Lu
Journal:  Am J Gastroenterol       Date:  2015-07-28       Impact factor: 10.864

Review 7.  The history of the "natural history" of hepatitis C (1968-2009).

Authors:  Leonard B Seeff
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

8.  Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.

Authors:  Uwe Siebert; Gaby Sroczynski; Pamela Aidelsburger; Siegbert Rossol; Jürgen Wasem; Michael P Manns; John G McHutchison; John B Wong
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong.

Authors:  D A Wong; L K Tong; W Lim
Journal:  Eur J Epidemiol       Date:  1998-07       Impact factor: 8.082

10.  Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment.

Authors:  Uwe Siebert; Gaby Sroczynski
Journal:  Ger Med Sci       Date:  2003-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.